MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Cellectar Biosciences Inc

Geschlossen

0.29 -3.33

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.28

Max

0.3

Schlüsselkennzahlen

By Trading Economics

Angestellte

11

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+233.33% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.2M

16M

Vorheriger Eröffnungskurs

3.62

Vorheriger Schlusskurs

0.29

Cellectar Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Dez. 2024, 18:44 UTC

Wichtige Markttreiber

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Peer-Vergleich

Kursveränderung

Cellectar Biosciences Inc Prognose

Kursziel

By TipRanks

233.33% Vorteil

12-Monats-Prognose

Durchschnitt 1 USD  233.33%

Hoch 1 USD

Tief 1 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cellectar Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Finanzen

$

Über Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.